[Congressional Record Volume 153, Number 95 (Wednesday, June 13, 2007)]
[Senate]
[Page S7631]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]




                           HONORING IMMUCELL

 Ms. SNOWE. Madam President, I wish to recognize a tremendously 
innovative small business from my home State of Maine that recently 
opened an upgraded production facility to benefit both its employees 
and its business operations. Immucell, an emerging biotechnology 
company based in Portland, opened its newly expanded building on June 7 
to great fanfare. The new facility benefits Immucell's 30 employees, 
who now have enhanced space and equipment with which to conduct 
research and manufacture products. Equally as critical, the facility 
was designed to help Immucell more easily comply with current good 
manufacturing practice standards. Enforced by the U.S. Food and Drug 
Administration, current good manufacturing practice requirements assure 
quality in our food and medicines.
  Immucell's specialized work is quite impressive. In a rapidly 
expanding biotech industry, Immucell has carved out a niche as a 
leading producer of medicines for animals in the dairy industry. The 
company's products, such as First Defense and Mast-Out, have ensured 
the safety and health of cows and calves that supply our milk and other 
dairy products. Working together with Pfizer, Immucell has managed to 
turn Mast-Out into a profitable product. Besides its products, 
Immucell's research provides the company a respected and prestigious 
role in the animal-health industry.
  I was delighted to hear that Immucell is seeking to use its expanded 
facilities to extend its reach into overseas markets. What a great 
honor that would be for the State of Maine. Immucell contributes 
immensely to Maine's small business community, and the ever-increasing 
relevance of its work also places it at the forefront of modern science 
worldwide.
  Immucell's efforts to become a leader in its market are noteworthy, 
and the vision that its leadership has for future growth reflects a 
steadfast determination for continued success. It is particularly 
exciting that a Maine small business is making such a name for itself 
in an industry replete with large companies. Immucell and its high-
paying jobs provide us with a shining example of smart growth. I 
commend chief executive officer Michael Brigham and all the employees 
at Immucell for their wise choices and tremendous achievements, and I 
wish them much success in the future.

                          ____________________